Zynerba initiated with a Buy at Roth Capital. Roth Capital analyst Jerry Isaacson started Zynerba Pharmaceuticals with a Buy rating and $36 price target, telling investors that while the company’s lead Fragile X Syndrome program is valuable, Zynerba’s pipeline programs have more potential value. The next program in development is for developmental and epileptic encephalopathy, noted Isaacson, who values the potential of Zygel for the treatment of FXS at $5 per share and for DEE at $28 per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.